LONDON (Reuters) -Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff wars, hoping to avert price spikes on top-selling medicines ...

For Maria Rising, managing her health felt like chasing a phantom. The 30-year-old Lansing, Mich. consultant has for years ...

US medical giants say Australia’s Pharmaceutical Benefits Scheme is an “egregious and discriminatory” program that Trump ...

A vial of Botox, sold by AbbVie, is seen next to its packaging in a photo illustration in Manhattan ... selling medicines made in Europe from Novo Nordisk's Wegovy for weight loss to Merck's ...

While weight-loss drugs like Zepbound (LLY) and Wegovy (NVO) offer significant health benefits, their high costs make them economically inefficient under current U.S. healthcare standards, according ...

The health sector provides a stark illustration of the consequences ... amongst women and those from diverse backgrounds. Novo Nordisk has reached the end of its two-year suspension from the ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo ...

While medications provide temporary weight-loss solutions, experts stress lifestyle changes as the most effective way to ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

For example, Novo Nordisk partially makes some of the active pharmaceutical ingredient for obesity injection Wegovy in Denmark, while Merck's mega-blockbuster Keytruda and AbbVie's (ABBV.N), opens ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...